<DOC>
	<DOC>NCT00126022</DOC>
	<brief_summary>The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.</brief_summary>
	<brief_title>Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Tedisamil</mesh_term>
	<criteria>Willing to sign informed consent before screening examinations are performed and before the study drug is administered Females &gt; 18 years of age Subjects with documented (60 second rhythm strip) symptomatic atrial fibrillation or flutter (duration &gt; 3 hours and &lt; 45 days) at the time of randomization Subjects who are in no distress and hemodynamically stable (supine systolic blood pressure &gt; 90 mmHg and diastolic blood pressure &lt; 105 mmHg) Pregnancy and lactation Acute myocardial infarction and cerebrovascular accidents Coronary syndromes and congestive heart failure (CHF) New York Heart Association (NYHA) IV Lifethreatening ventricular arrhythmias and electrocardiogram (ECG) abnormalities Concurrent antiarrhythmic treatments</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>atrial flutter</keyword>
	<keyword>anti-arrhythmic agents</keyword>
	<keyword>conversion to normal sinus rhythm</keyword>
</DOC>